β Home
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights π’ Company Q&A (465) π οΈ Industry Q&A (98) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ§© Revenue Segmentation by Product
Switch to Location
| Fiscal year | Segment | Value |
|---|---|---|
| 2024 | Duodopa | 447M |
| 2024 | Lumigan/Ganfort | 429M |
| 2024 | Imbruvica | 3.35B |
| 2024 | Vraylar | 3.27B |
| 2024 | Alphagan/Combigan | 248M |
| 2024 | Other Eye Care | 847M |
| 2024 | H U M I R A | 8.99B |
| 2024 | Other Neuroscience | 338M |
| 2024 | SKYRIZI | 11.72B |
π° Explore more revenue segmentation data for AbbVie!
Sign up for free or log inπ‘ Learn smarter stock picks with "The Checklist Value Investor β A Smarter Way to Pick Stocks"